BIIB054

DRUG3 trials

Sponsors

Biogen

Conditions

HealthyParkinson's Disease

Phase 1

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

CompletedNCT02459886

BiogenHealthy, Parkinson's Disease

Start: 2015-07-01End: 2017-11-20Updated: 2019-08-08

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

TerminatedNCT03716570

BiogenParkinson's Disease

Start: 2019-03-12End: 2021-04-23Updated: 2021-05-25

Phase 2

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

TerminatedNCT03318523

BiogenParkinson's Disease

Start: 2018-01-10End: 2021-04-29Updated: 2022-02-28

Related Papers

Cinpanemab in Early Parkinson Disease

Neurology2024-02-0525 citations

Trial of Cinpanemab in Early Parkinson’s Disease

New England Journal of Medicine2022-08-03306 citations

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.

2021-11-2315 citations

Use of Multimodal Imaging in a Phase 2 Study in Participants with Parkinson’s Disease (SPARK) (1516)

Neurology2020-04-14

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Movement Disorders2019-06-17186 citations

Antibody-based immunotherapies for Parkinsonian syndromes

Neural Regeneration Research2019-01-014 citations